G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 juin 2022 16h45 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1 Therapeutics Named 2022 Life Sciences Public Company of the Year by Triangle Business Journal
20 mai 2022 10h30 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it received Triangle Business Journal's...
G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conference
18 mai 2022 10h15 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 18, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive...
G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights
04 mai 2022 06h30 HE
|
G1 Therapeutics
- Achieved $6.9 Million in Total Revenue in the First Quarter of 2022, Including $5.5 Million in Net Revenue from Sales of COSELA™ (trilaciclib) - - Fully Deployed G1’s COSELA Sales Team as of...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 mai 2022 17h30 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 02, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1 Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 4, 2022
21 avr. 2022 08h30 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., April 21, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a...
G1 Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
06 avr. 2022 11h30 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., April 06, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey and Raj Malik, M.D., G1’s...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 avr. 2022 16h15 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., April 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
New Real-World Data Show Potential of Trilaciclib to Reduce the Substantial Burden of Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with Chemotherapy
31 mars 2022 16h05 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., March 31, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced results of a retrospective, observational...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 mars 2022 17h00 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., March 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...